Nanoform Finland Plc and Celanese Corporation provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. Together, the API nanoparticles produced through Nanoform's CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nano formed particles also allows smaller implants with sustained release properties to be developed.